Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Diagluc | Cosmos Limited. | Cosmos Limited | 80mg | 28 | Tablet | per tablet | KES 300 |
| Diapro | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 80mg | 30 | Tablet | per tablet | KES 880.00 |
| Getzid MR | Getz Pharmaceuticals | Surgipharm Ltd | 30mg | 30 | Tablet | per tablet | KES 420 |
| Glycigon | Aristo Pharmaceuticals Ltd. | Medisel Kenya Ltd | 80mg | 100 | Tablet | per tablet | KES 1,500.00 |
| Glycinorm MR | IPCA | Sai Pharmaceuticals Ltd. | 30mg | 30 | Tablet | per tablet | KES 539.00 |
| Remicron MR | Ranbaxy Laboratories | Pharma Specialities Ltd. | 30mg | 30 | Tablet | per tablet | KES 664.00 |
| Glizarem | Remedica Ltd. | Twokay Chemicals Ltd | 80mg | 30 | Tablet | per tablet | KES 350.00 |
| Gliclazide More info | |
|---|---|
| Mode Of Action | Sulphonylurea -antidiabetics like chlorpropamide act mainly by directly stimulating the release of insulin from functioning beta cells of pancreatic islet tissue. To achieve this, they inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux. This results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis. |
| Drug Indication | Uncomplicated and non-ketonic diabetes mellitus (maturity onset type II diabetes) |
| Precautions | Maintain regular medical monitoring; elderly; barbiturate therapy; dietetic therapy in obese; Addisons disease; and disulfiram-like reactions. |
| Contra-Indications | Patients allergic to gliclazide; patients with diabetes requiring insulin; diabetes complicated with by acidosis and ketosis; diabetic glaucoma; severe hepatic or /and renal failure; porphyria; breast feeding; |
| Side Effects | GI disturbances; blood dyscrasia; hypoglycaemia; jaundice; skin rashes; hypersensitivity reactions; headache; dizziness; oedema; hyponatraemia; paraesthesia; photosensitivity. |
| Dosage | Dose for Gliclazide MR 60mg:One half to 2 tablets per day, i.e. 30 to 120 mg depending on response, as a single daily intake at breakfast time, including in elderly patients or those with mild-to-moderate renal failure. Dose for controlled release formulation: Initially 60mg OD at breakfast; increase dose according to response, by 30mg OD at not less than 2-week intervals (max. daily dose 120mg.)Start at 30mg for the elderly and in renal impairment.Dose for non-controlled release formulation of gliclazide: Initially 40-320mg daily in 1-2 doses. Max single dose 160mg. Max. daily dose 320mg.Dose for non-controlled release formulation of gliclazide: Initially 40-320mg daily in 1-2 doses. Max single dose 160mg. Max. daily dose 320mg. |
| Special Information | Glycemia independent hemovascular effects, antioxidant effect. It has no active circulating metabolite. |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Sulphonylureas |